Encompass Health stock holds near USD 122 as targets rise

Encompass Health Corporation (ISIN US29251A1043) closed at USD 121.75 on Nasdaq on September 18, 2026, giving the stock a firm reference point as analysts kept targets above the market price. The Globe and Mail reported on September 22, 2026, that Deutsche Bank maintained a Buy rating and a USD 142.00 price target.

Analysts keep targets above price

The Deutsche Bank target stood USD 20.25 above the September 18 closing price, equivalent to 16.6 percent of that reference price. The Globe and Mail also reported on September 22, 2026, that KeyBanc maintained a Buy rating with a USD 147.00 target, USD 25.25 above the same close.

The two targets create a concrete valuation comparison: USD 142.00 and USD 147.00 versus USD 121.75. The reported analyst consensus was Strong Buy with an average target of USD 146.78, which the report described as 19.1 percent above the prevailing level.

Healthcare operations remain central

Encompass Health operates in the rehabilitation hospital industry, where revenue, earnings and capacity growth remain the financial measures most relevant to the equity case. The latest source-covered analyst update in this result set identifies the company and its stock ticker but does not provide a new quarterly revenue or earnings figure with a reporting period.

That makes the target spread the clearest quantified current comparison: the average target of USD 146.78 was USD 25.03 above the September 18 close, while the highest named target of USD 147.00 was USD 25.25 higher. The difference between the two named analyst targets was USD 5.00.

Nasdaq price sets the reference

For the article's market reference, Encompass Health traded under ticker EHC on Nasdaq in USD. The dated close of USD 121.75 on September 18, 2026, is the price used for the comparison with the Deutsche Bank, KeyBanc and consensus targets.

More news and analyses on Encompass Health stock